Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could blood filtering ease long COVID? new trial aims to find out

NCT ID NCT07316127

Recruiting now Disease control Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

Some people with long COVID have harmful antibodies that may be attacking their own bodies, causing severe fatigue and other symptoms. This study tests a treatment called immunoadsorption, which filters the blood to remove those antibodies. About 70 participants will receive either the real treatment or a sham procedure, and researchers will track changes in fatigue and daily function over six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Immunoadsorption (blood filtering device using tryptophan columns)
What this could lead to
If it works, this could point toward a treatment for long COVID patients whose symptoms are driven by autoimmune antibodies.
What could go wrong
This is a small, early-phase trial with only 70 participants. The treatment is invasive and may not work for all long COVID patients. Risks include side effects from blood filtering.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19 post-COVID-19 disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LONG COVID LONG COVID SYNDROME LONG COVID-19 SYNDROME POST-COVID SYNDROME

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AUMC

    RECRUITING

    Amsterdam, Netherlands

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.